Lamellar Body Counts: Clinical Utility and Test Validation (by ASCLS)
This course does not carry any current continuing education credits.
Danelle Beaudoin, PhD Course provided by ASCLS.
See more courses in: Hematology
Objectives
- Describe the stages of normal lung developement.
- Define Respiratory Distress Syndrome (RDS).
- Discuss methods used for detecting Fetal Lung Maturity (FLM).
- Review the Lamellar Body Count (LBC) validation process.
Course Outline
- ASCLS - LBC 2013 - Presentation
- Introduction
- Fetal Lung Development
- First (3) Developmental Stages
- Final (2) Developmental Stages
- Lung Anatomy
- Functional Units - Alveoli
- Alveolar Cells
- Surfactant
- Respiratory Distress Syndrome (RDS)
- Insufficient Surfactant
- Risk Factors
- RDS Treatment
- Testing Indications
- FLM Qualifications
- Test Quality Indicators
- Testing Overview
- Test Performance
- Test Utilization
- Why Test?
- Lamellar Body Count
- LDT vs FDA-Approved Testing (I)
- LDT vs FDA-Approved Testing (II)
- How To Get Started?
- Consensus Protocol For LBC
- Precision
- AMR (Linearity) - Sysmex-XE
- Limit of Blank
- Limit of Detection
- Limit of Quantitation
- Accuracy - Patient Comparisons
- LBC vs. S/A Ratio (TDX-FLM II)
- Four LBC Methods
- Instrument Model Is Important
- Extrapolating From Reference Method
- Interference - Hemolysis
- Interferences - Meconium
- Sample Stability
- Quality Assurance
- Summary
- References (I)
- References (II)
|
How to Subscribe
- Order for instant access through any computer, any browser.
- No shipping, faxing, or waiting for certificates.
- Print or save your certificate of completion as soon as you've completed the course.
- You'll have 90 days to complete your purchased courses.
Course provided by ASCLS.
|